Patients with type 2 diabetes mellitus (T2DM) patients are at increased risk of vertebral fractures (VFs) compared with non-T2DM individuals, because of poor bone quality. Recent studies in nondiabetic subjects have shown that elevated sclerostin levels are associated with VFs independent of bone mineral density (BMD).
T
he association between diabetes mellitus and osteoporosis has been extensively investigated because both disorders affect a large proportion of elderly people. Metaanalyses have determined that patients with type 2 diabetes mellitus (T2DM) are at increased risk of hip fracture compared with non-T2DM controls (1, 2) . We have previously reported that patients with T2DM exhibit a significantly elevated risk of vertebral fractures (VFs) despite their elevated bone mineral density (BMD) compared with nondiabetic controls (3). It is difficult for patients with T2DM to assess their bone fragility by BMD because BMD at any site fails to accurately assess the risk of VFs (3) and because the fracture risk is elevated for a given T score and age compared with nondiabetic control subjects (4) . Bone strength is a composite of both bone density and bone quality (5) ; thus, these findings suggest that patients with T2DM might exhibit poor bone quality that is not apparent in the BMD measurements.
Sclerostin is a glycoprotein mainly secreted by osteocytes (6) and acts as an antagonist for the Wnt/␤-catenin canonical signaling pathway (7) (8) (9) , which is involved in osteoblastogenesis and bone formation, by binding to low-density lipoprotein receptor-related protein 5 or 6 on the osteoblastic cells. Recently, two cohort studies have demonstrated that women with elevated sclerostin levels or in the highest sclerostin quartile were at an increased risk of fracture after adjusting for multiple variables including BMD (10, 11) . These findings suggested that elevated sclerostin levels cause bone fragility by deteriorating bone quality independent of BMD. However, the association between sclerostin levels and low bone strength due to poor bone quality in patients with T2DM has not been established.
To clarify this issue, we investigated the determinant factors affecting sclerostin levels and examined the relationship between sclerostin levels and the presence of VFs in patients with T2DM.
Subjects and Methods

Subjects
We enrolled 321 Japanese patients with T2DM (146 postmenopausal women [age range 46 -83 years] and 175 men [age range 50 -87 years]) who underwent BMD measurements at the outpatient clinic of Shimane University Hospital. The patients had been referred to our hospital from community clinics for the treatment of diabetes. We excluded subjects from both groups who had higher-than-normal serum creatinine (Cr) levels (normal range for women, 0.44 -0.83 mg/dL; for men, 0.56 -1.23 mg/dL). We also excluded subjects with primary hyperparathyroidism, hyperthyroidism, rheumatoid arthritis, alcoholism, or a history of falls or traffic accidents to eliminate the possibility of injury-associated fractures. In the diabetic group, 17 (11.6%), 33 (22.6%), 58 (39.7%), and 31 (21.2%) women and 19 (10.8%), 32 (18.2%), 72 (41.1%), and 26 (18.9%) men had been taking pioglitazone, metformin, sulfonylurea, and insulin therapies, respectively. None of the subjects received drugs or hormones that might affect their bone metabolism, including sex steroids, glucocorticoids, warfarin, bisphosphonates, teriparatide, denosmab, and strontium ranelate. This cross-sectional study was approved by the ethical review board of our institution and complied with the Helsinki Declaration. All of the subjects agreed to participate in the study and provided written informed consent.
Biochemical measurements
We obtained blood samples from fasting patients and measured the concentrations of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), serum Cr, serum calcium (Ca), and serum phosphate (P) using automated techniques at our hospital's central laboratory. Serum bone-specific alkaline phosphatase (BAP) and urinary N-telopeptide (uNTX) were measured using commercially available ELISAs. Serum concentrations of intact PTH were measured using an electrochemiluminescence immunoassay. Sclerostin was measured by ELISA using biotinylated antibody/horseradish peroxidase-streptavidin provided by Biomedica Medizinprodukte GmbH and Co KG (intra-and interassay coefficients of variation were 4%-6% and 5%-7%, respectively). The assays were performed following the manufacturers' instructions and using the reagents and materials provided by the manufacturers. Briefly, aliquots of the sample were stored at Ϫ80°C until the time of the assay. All samples were brought to room temperature, and 150 L assay buffer was added per well, followed by 20 L standard or sample and 50 L antisclerostin antibody. Plates were covered and incubated for 20 hours at 20°C in the dark. Wells were washed 5 times, and 200 L conjugate was added to each well and incubated for 1 hour at 20°C in the dark. Wells were washed 5 times, and 200 L substrate was added per well. The color reaction was allowed to develop for 30 minutes at 20°C, followed by the addition of 50 L stop solution. Absorbance was measured immediately at 450 nm with reference 620 nm.
BMD measurements
BMD values for the lumbar spine (L) and the femoral neck (FN) were measured by dual-energy x-ray absorptiometry, using a QDR-4500 system (Hologic). The values were expressed relative to the SD of age-and sex-matched normal Japanese BMD values provided by the manufacturer (Z score). The coefficients of variation for the measurements of L-BMD and FN-BMD were less than 1%.
Ascertainment of fractures
For all of the subjects, we obtained the conventional thoracic and spinal radiographs using lateral and anteroposterior projections. A VF was diagnosed if a reduction of Ն20%, according to the Genant visual criteria (12) , was observed by 2 investigators who were blinded to each other's readings. If the VF assessments did not agree, the film was independently reassessed. If the re- 
Statistical analysis
The sclerostin levels were converted to natural logarithms, log (sclerostin), for statistical analysis of the linearity because the distribution of plasma sclerostin was skewed, and the normality of the distributions were confirmed by Kolmogorov-Smirnov test. All parameters are presented as the mean Ϯ SD for each group. The statistical analyses were conducted using StatView (Abacus Concepts, Inc). The statistical significance of continuous variables was determined using the Mann-Whitney U test, whereas categorical variables were evaluated using the 2 test. Stepwise regression analyses were performed to determine the independent variables of sclerostin levels. The multiple logistic regression analysis was performed after adjusting for the variables shown in the tables. P values Ͻ.05 were considered significant.
Results
Baseline characteristics of T2DM patients
The background data are shown in Table 1 . There were 47 women (32.2%) and 72 men (41.1%) with VFs. There were no significant differences in age, the duration of T2DM, and the serum levels of fasting glucose, HbA1c, and intact PTH between the men and the women. The men with T2DM exhibited significantly higher Cr levels, BMD values, and T and Z scores at the spine and FN compared with the women (at least P Ͻ .05). The serum concentrations of corrected calcium, phosphate, BAP, and uNTX in the men's group were significantly lower than those in the women's group (at least P Ͻ .05). The serum sclerostin levels as well as the log (sclerostin) of the diabetic men were significantly higher than those of the diabetic women (P Ͻ .01). The prescription rates of pioglitazone, metformin, sulfonylurea, and insulin did not significantly differ between these groups.
Correlations of serum sclerostin levels with glucose and bone metabolic marker levels
The factors affecting the sclerostin levels were investigated by simple regression analysis ( Table 2 ). The sclerostin levels of both genders were significantly and positively correlated with the L-and FN-BMD, their T and Z scores, and the Cr levels and were significantly and inversely associated with bone metabolic markers. The calcium levels in the women's group and the age and the duration of T2DM in the men's group were significantly and positively associated with the sclerostin levels. The same factors were also significantly correlated with log (sclerostin) levels.
To determine the independent factors affecting the sclerostin levels, stepwise forward multiple regression analyses were performed with the variables that were significantly correlated by simple regression analysis. The L-BMD values were the strongest independent positive determinants for the sclerostin levels in both the women (r ϭ 0.382, F ϭ 28.2) and the men (r ϭ 0.391-0.398, F ϭ 34.5-36.5) ( Table 3 ). The Cr levels were the second strongest and were independent positive factors associated with the sclerostin levels in the women's group. Sclerostin levels in the men's group were weak positively and inversely correlated with age and bone formation as well as with resorption markers, respectively. These findings remained significant in the analyses for log (sclerostin), with the exception of calcium levels in the women's group.
Assessment of VF risk between the patients with and without VFs
The biochemical parameters between the patients with and without VFs were compared in all of the patients in the women's group (Table 4 ) and the men's group (Table 5 ). In the analysis for all of the patients, the serum sclerostin levels of patients with VF were significantly higher than those of patients without VF in the men's group (1.925 Ϯ 0.808 vs 1.695 Ϯ 0.581 ng/mL, P Ͻ .05). However, there was no significant difference in the log (sclerostin) levels in patients with and without VF in both genders. The patients with VFs were significantly older and had lower serum phosphate levels in both genders (at least P Ͻ .05). The women patients with VFs had a significantly longer duration of T2DM, higher uNTX levels, and lower FN-BMD values than those without VFs. The values of FPG, HbA1c, calcium levels in T2DM men with VFs were significantly lower than those without VFs.
To investigate the association between the sclerostin levels and the risk of VF, we performed logistic regression analyses (Figure 1 ). Analyzing all of the participants, the sclerostin levels were positively related to the risk of VFs in the men's group (odds ratio [OR] ϭ 1.40, 95% confidence interval [CI] ϭ 1.03-1.91 per 1 SD increase, P Ͻ .05). However, after adjusting for age, BMI, HbA1c, Cr, duration of T2DM, calcium, and phosphate (model 1), the relationships between sclerostin and the risk of VF were not significant in either gender. When L-BMD was added to these adjusted variables (model 2), the sclerostin levels were significantly and positively associated with the risk of VF in both genders (women: OR ϭ 1.68, 95% CI ϭ 1.04 -2.70, P Ͻ .05; men: OR ϭ 1.52, 95% CI ϭ 1.01-2.30, P Ͻ .05). These findings remained significant after the adjustments for bone metabolic markers (BAP and uNTX) and diabetic medications (pioglitazone, metformin, sulfonylurea, and insulin use) (model 3) (women: OR ϭ 1.93, 95% CI ϭ 1.17-3.18, P Ͻ .05; men: OR ϭ 1.54, 95% CI ϭ 1.01-2.34, P Ͻ .05).
These findings suggested that the association between sclerostin levels and the risk of VF was impacted by L-BMD. Therefore, the participants were divided into 2 subgroups according to T scores of spine BMD, L-BMD T score ϽϪ1 and T score ՆϪ1, to eliminate the influence of BMD on sclerostin values. Similar statistical analyses were then performed in each subgroup. The women with VF in the L-BMD T score ϽϪ1 subgroup exhibited significantly higher sclerostin levels than those without VF (1.078 Ϯ 0.430 vs 0.917 Ϯ 0.239 ng/mL, P Ͻ .05), and there were no significant differences in any of the other independent variables between patients with and without VF, except for phosphate levels (Table 4 ). In the men's subgroup of L-BMD T score ՆϪ1, the sclerostin levels were significantly higher in the patients with VF compared with those in the patients without VF (2.095 Ϯ 0.782 vs 1.813 Ϯ Table 5 ). The logistic analyses revealed that the elevated sclerostin levels in these subgroups were significantly and consistently associated with an increased risk of VF after adjustments for model 3 (women's subgroup T score ϽϪ1: OR ϭ 3.23, 95% CI ϭ 1.42-7.34, P Ͻ .01; men's subgroup T score ՆϪ1: OR ϭ 1.85, 95% CI ϭ 1.12-3.07, P Ͻ .05) (Figure 1 ). These significantly increased risks of VF in these subgroups were also observed when statistical procedures were performed with log (sclerostin) levels instead of sclerostin levels except for the group including all of the male participants (Supplemental Figure 1 , published on The Endocrine Society's Journals Online website at http://jcem.endojournals.org).
Discussion
In this study, we demonstrated that sclerostin levels exhibited a strong positive correlation with L-BMD in both genders and a weak and limited inverse relationship with bone metabolic markers by stepwise regression analysis. Additionally, the sclerostin levels were significantly and positively associated with the risk of VF, which exhibited a relationship that was independent of L-BMD, bone turnover, and diabetic medications in both genders.
Several studies have reported the associations between sclerostin levels and bone metabolism in the elderly. Most studies, but not all (13, 14) , reported that circulating sclerostin levels are positively correlated with age (15) (16) (17) . BMD levels are known to decrease with age; therefore, sclerostin levels are likely to be inversely correlated with BMD. However, many studies, with the exception of one (16) , reported that sclerostin levels are positively associated with BMD in nondiabetic women and men (11, 13-15, 18, 19) as well as in patients with diabetes (17) . These findings are supported by reports that bone formation markers (BAP and N-terminal propeptide of type I procollagen) and resorption markers (C-terminal telopeptide of type I collagen and deoxypyridinoline) are inversely correlated with sclerostin in nondiabetic subjects (15, 18, 19) after adjustment for age at least. In the present study, sclerostin levels showed a positive correlation with BMD in both sexes and with age in the men's group and exhibited a negative relationship with bone turnover in the men's group after a stepwise regression analysis. These findings suggested that the associations between sclerostin levels and bone turnover as well as BMD in the patients with T2DM were consistent with those in nondiabetic subjects.
The relationships between sclerostin levels and the risk of fracture are controversial. Two population-based stud- ies in postmenopausal women reported that elevated sclerostin levels were a risk factor for osteoporotic fracture even after adjustment for BMD (10, 11) . In contrast, a cross-sectional study in elderly women and a prospective study in men over 50 years of age reported that sclerostin levels have an absent or a negative relationship with the risk of fracture (18, 19) . In the present study, we found that the relationship between sclerostin levels and the risk of VF significantly differed between the subgroups with T score ϽϪ1 and T score ՆϪ1. This observation suggested that these relationships were confounded by the specific range of BMD in each gender. Sclerostin levels are significantly correlated with BMD; thus, these values represent the amount of bone mass, suggesting that elevated sclerostin levels may be potentially correlated with a decreased risk of fracture. In another aspect, sclerostin is secreted from deeply embedded osteocytes that are in matured bone tissue, not from early embedding osteoid osteocytes and young osteocytes (20) , suggesting that the sclerostin levels reflect the amount of aged bone mass, which may accumulate microfractures and cause an increased risk of fracture independent of BMD as well as bone turnover. Therefore, our results suggest that assessments of fracture risk by sclerostin levels need Figure 1 . Associations between the presence of VFs and the sclerostin levels in all of the participants as well as in the subgroups stratified by spine T score. Logistic analyses were performed for all of the participants as well as for the subgroups stratified by spine T scores (ϽϪ1 or ՆϪ1) for each gender. The sclerostin levels were associated with an increased risk of VF in the group, including all of the participants, in women with T score ϽϪ1 and in men with T score ՆϪ1 after adjustment for multiple variables listed below. Model 1 was adjusted for age, BMI, HbA1c, Cr, duration of T2DM, calcium, and phosphate. Model 2 was adjusted as for model 1 and additionally adjusted for L-BMD. Model 3 was adjusted as for model 2 and additionally adjusted for BAP, uNTX, and the use of pioglitazone, metformin, sulfonylurea, and insulin. to be applied in participants stratified by BMD T-scores to eliminate the influence of bone mass upon sclerostin levels. Our results further suggest that sclerostin levels may potentially assess bone fragility independent of BMD under these T score ranges. This study demonstrated for the first time that there is an association between sclerostin levels and VFs in patients withT2DM. Three previous studies have been performed with a small number of mixed T2DM patients (the number of participants were 11 and 22 men and 33 and 44 women, respectively) (17, 21) and with 40 postmenopausal women with T2DM (22) . Two of these studies reported that the sclerostin levels exhibited no significant relationship with VF in patients with T2DM (17, 22) , and the third study did not investigate the risk of VF (21) . In contrast, the number of participants in the present study was larger than these previous studies, and the statistical procedure was performed according to gender. These differences may explain why the previous studies could not identify the relationship between sclerostin levels and VF.
All Patients
There is no established consensus on the sclerostin levels of patients with T2DM. Previous studies have reported that sclerostin levels in a mixed group of T2DM men and women were significantly higher than those in a similar mixed group of non-T2DM control subjects that did not significantly differ in the sex ratio (17, 21) . However, several studies including the present study demonstrated that the sclerostin concentrations in men were significantly higher than those in women, irrespective of the presence of T2DM (15, 17, 23) , which suggests that the sclerostin levels should be compared by gender. On the other hand, one study reported that the sclerostin levels of male patients with T2DM were significantly higher than those of nondiabetic subjects whose age did not significantly differ from the diabetic patients without adjusting for BMD (24) . The present study revealed that BMD values robustly and positively affect sclerostin levels in patients with T2DM. Other studies have demonstrated that sclerostin concentrations are significantly increased with age (15) (16) (17) . Taken together, age-, sex-, and BMD-matched or adjusted comparisons are required to clarify whether the sclerostin levels of patients with T2DM are higher than those of non-T2DM subjects.
The participants in this study included patients treated with thiazolidinediones, which are known to be associated with the risk of fracture (25) , and elevated sclerostin concentrations (24) , suggesting that the treatment of pioglitazone may affect the risk of VF and sclerostin levels in this study. We confirmed that significant differences were not observed in the VF rates, sclerostin levels, log (sclerostin) levels, L-BMD, and FN-BMD between the patients treated with and without pioglitazone in the women's group , and 0.800 Ϯ 0.133 vs 0.781 Ϯ 0.126 g/cm 2 , respectively) in this study. Recently, a meta-analysis composed of 3 large-scale, population-based cohort studies revealed that patients with T2DM exposed to thiazolidinediones have an increased risk for fractures of the extremities, not for VFs, compared with the patients exposed to other antidiabetic drugs (26) . These observations suggested that the exposure to pioglitazone may not impact the sclerostin levels and the risk of VF in this study. This study had several limitations. First, this study was not population-based, nor were all of the participants enrolled from identical populations; thus, a selection bias might have occurred. The sample size was not large enough to enable us to make definitive conclusions. Second, the patients enrolled in this study were treated at Shimane University Hospital, a tertiary care center, and thus may exhibit more severe cases of T2DM; therefore, our patients might not be representative of average Japanese patients with T2DM. Third, this study could not provide several background data affecting osteoporosis such as the family history of hip fracture, medication of anticonvulsants, and rate of vitamin D insufficiency. Fourth, sample size was too small to divide the stratified subgroup of T score by sclerostin levels to eliminate the skewed distribution of sclerostin for the statistical analysis of the linearity. Therefore, the sclerostin levels were converted into natural logarithms. However, the statistical results performed with sclerostin levels were similar to those with log (sclerostin) levels in this study, suggesting that sclerostin levels may be adequate to use for the statistical analysis of the linearity in this study. The reasons for the differences between men and women in the ranges of T score in which the association between VF and sclerostin levels was established are unknown. Further studies are needed to clarify this pathophysiology.
In conclusion, we found that elevated sclerostin levels were associated with an increased risk of VF in the patients with T2DM in the women's group with T scores ϽϪ1 and in the men's group with T scores ՆϪ1. These relationships were independent of BMD and bone turnover, suggesting that sclerostin levels may reflect bone fragility attributed to the deterioration of bone quality. The assessment of bone fragility with BMD is difficult for the patients with T2DM (3, 4) . Therefore, measurements of sclerostin levels in patients with T2DM in the subgroup of the specific range of BMD T scores mentioned above may be helpful in identifying bone fragility caused by poor bone quality.
